Key financial metrics revealed a 1% decrease in group revenues to €575.7 million, primarily due to a 12% decline in the Shared R&D segment. However, the Just – Evotec Biologics segment experienced a 74% increase in revenues, reaching €128.7 million. Despite these mixed results, adjusted Group EBITDA fell to a negative €6.0 million, impacted by increased costs and ongoing reorganization efforts. Strategic alliances have been a focal point, with significant developments in technology partnerships and collaborative agreements. Additionally, the company opened a new biologics facility in Toulouse, France, indicating a commitment to expanding its operational footprint.